Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin
Carcinoma of Unknown Primary, Colorectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific
About this trial
This is an interventional treatment trial for Carcinoma of Unknown Primary focused on measuring stage III colon cancer, stage IV colon cancer, stage III rectal cancer, stage IV rectal cancer, unspecified childhood solid tumor, protocol specific, unspecified adult solid tumor, protocol specific, adenocarcinoma of unknown primary, newly diagnosed carcinoma of unknown primary, recurrent carcinoma of unknown primary
Eligibility Criteria
DISEASE CHARACTERISTICS: One of the following diagnoses: Histologically proven previously untreated stage III or stage IV colorectal carcinoma Other carcinomas refractory to standard treatment Metastatic adenocarcinoma of unknown primary site PATIENT CHARACTERISTICS: Age: Under 25 Performance status: ECOG 0-2 Life expectancy: At least 8 weeks Hematopoietic: Hemoglobin at least 10.0 g/dL Absolute neutrophil count at least 1,000/mm^3 Platelet count at least 100,000/mm^3 Hepatic: Albumin greater than 3.0 g/dL Bilirubin less than 1.5 mg/dL SGOT or SGPT less than 2 times normal Renal: Creatinine less than 1.5 mg/dL OR Creatinine clearance greater than 80 mL/min Urinalysis normal Other: Blood glucose normal Electrolytes normal Prior curatively treated childhood cancer allowed Weight greater than 10th percentile for height Not pregnant or nursing Negative pregnancy test PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy Not specified Endocrine therapy Not specified Radiotherapy Not specified Surgery Not specified
Sites / Locations
- St. Jude Children's Research Hospital